💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

BRIEF-Resverlogix says proposed Phase 2A kidney dialysis study design to be separated in two parts

Published 2017-02-23, 07:24 a/m
© Reuters.  BRIEF-Resverlogix says proposed Phase 2A kidney dialysis study design to be separated in two parts
RVX
-

Feb 23 (Reuters) - Resverlogix Corp RVX.TO :

* Resverlogix - study to evaluate if treatment with apabetalone with standard of care decreases alkaline phosphatase in comparison to placebo and soc

* Resverlogix reports positive FDA type B meeting on design issues relating to a proposed phase 2A kidney dialysis trial

* Resverlogix Corp - in light of guidance received from FDA, phase 2A study design will be separated in two parts

* Resverlogix Corp - part a of study will involve a single-dose pharmacokinetic (PK) study in eight patients receiving hemodialysis

* Resverlogix Corp - PK results from part a will influence dose selection for part B study

* Resverlogix Corp - part B study will be a double-blind, randomized, placebo-controlled, sequential cross-over study with apabetalone

* Resverlogix Corp - intends to file an official investigative new drug (IND) application and proceed with planned phase 2A clinical trial in 2017 Source text for Eikon: ID:nCNWLcGy9a Further company coverage: RVX.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.